|
"hsiao cf"的相關文件
顯示項目 6-30 / 204 (共9頁)
1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai, HJ;Yang, SH;Hsiao, CF;Kao, HF;Su, YY;Shan, YS;Yen, CJ;Du, JS;Hsu, C;Wu, IC;Chen, LT |
| 國家衛生研究院 |
2023-11-13 |
Polygenic risk score, environmental tobacco smoke, and risk of lung adenocarcinoma in never-smoking women in Taiwan
|
Blechter, B;Chien, LH;Chen, TY;Chang, IS;Choudhury, PP;Hsiao, CF;Shu, XO;Wong, JYY;Chen, KY;Chang, GC;Tsai, YH;Su, WC;Huang, MS;Chen, YM;Chen, CY;Hung, HH;Hu, JW;Shi, J;Zheng, W;Rositch, AF;Chen, CJ;Chatterjee, N;Yang, PC;Rothman, N;Hsiung, CA;Lan, Q |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-11 |
The registry of genetic alterations of Taiwan NSCLC by comprehensive next-generation sequencing: A real-world cohort study - TCOG T1521 study
|
Liao, BC;Chiang, NJ;Chang, GC;Su, WC;Chong, IW;Yang, TY;Luo, YH;Lai, CL;Hsia, TC;Ho, CL;Lee, KY;Hsiao, CF;Yang, JCH |
| 國家衛生研究院 |
2023-01-10 |
Bayesian hierarchical models for adaptive basket trial designs
|
Chen, C;Hsiao, CF |
| 國家衛生研究院 |
2022-11 |
BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
|
Chiang, NJ;Hung, YP;Lien, MY;Wu, SY;Chang, WL;Bai, LY;Hsiao, CF;Chen, SH;Wu, IC;Chen, MH |
| 國家衛生研究院 |
2022-09-21 |
Recalibrating risk prediction models by synthesizing data sources: Adapting the lung cancer PLCO model for Taiwan
|
Chien, LH;Chen, TY;Chen, CH;Chen, KY;Hsiao, CF;Chang, GC;Tsai, YH;Su, WC;Huang, MS;Chen, YM;Chen, CY;Liang, SK;Chen, CY;Wang, CL;Hung, HH;Jiang, HF;Hu, JW;Rothman, N;Lan, Q;Liu, TW;Chen, CJ;Yang, PC;Chang, IS;Hsiung, CA |
| 國家衛生研究院 |
2022-07-18 |
Impaired chromatin remodeling predicts survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: A phase II T1219 study
|
Chiang, NJ;Tan, KT;Bai, LY;Hsiao, CF;Huang, CY;Hung, YP;Huang, CJ;Chen, SC;Shan, YS;Chao, Y;Huang, YH;Lee, IC;Lee, PC;Su, YY;Chen, SJ;Yeh, CN;Chen, LT;Chen, MH |
| 國家衛生研究院 |
2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer
|
Chen, MH;Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, LT |
| 國家衛生研究院 |
2022-06-02 |
Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma
|
Su, YY;Liu, YS;Hsiao, CF;Hsu, C;Chen, LT |
| 國家衛生研究院 |
2022-05-02 |
Three-stage pooled plasma hepatitis C virus RNA testing for the identification of acute HCV infections in at-risk populations
|
Sun, HY;Chiang, C;Huang, SH;Guo, WJ;Chuang, YC;Huang, YC;Yang, CJ;Su, LH;Chen, YT;Chen, YW;Hsu, FC;Ho, SY;Liu, WC;Su, YC;Chang, SY;Hsiao, CF;Hung, CC;Yu, ML |
| 國家衛生研究院 |
2022-01 |
Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients
|
Blanchard, P;Lee, AWM;Carmel, A;Wai Tong, N;Ma, J;Chan, ATC;Hong, RL;Chen, MY;Chen, L;Li, WF;Huang, PY;Kwong, DLW;Poh, SSX;Ngan, R;Mai, HQ;Ollivier, C;Fountzilas, G;Zhang, L;Bourhis, J;Aupérin, A;Lacas, B;Pignon, JP;Benhamou, E;Chakrabandhu, S;Tc Chan, A;Chen, QY;Chen, Y;Chappell, RJ;Choi, H;Tt Chua, D;Lee Kiang Chua, M;Higgins, J;Hong, MH;Hong, RL;Pun Hui, E;Hsiao, CF;Kam, M;Angeliki Koliou, G;Lw Kwong, D;Lai, SC;On Lam, K;LeBlanc, ML;Wm Lee, A;Fun Victor Lee, H;Fei Li, W;Ma, B;Mo, F;Moon, J;Tong Ng, W;O'Sullivan, B;Petit, C;Pierre Pignon, J;Poh, SX;Rücker, G;Sham, J;Lim Soong, Y;Sun, Y;Tan, T;Tang, LQ;Tung, Y;Wee, J;Wu, X;Xu, T;Zhang, Y;Zhu, G;on behalf of the MACNPCcG |
| 國家衛生研究院 |
2021-11-12 |
The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience
|
Tsai, HJ;Hsiao, CF;Chang, JS;Chen, LT;Chao, YJ;Yen, CJ;Shan, YS |
| 國家衛生研究院 |
2021-10-27 |
Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances
|
Wu, YJ;Cheng, YC;Chiang, C;Cheng, LH;Liu, CT;Hsiao, CF |
| 國家衛生研究院 |
2021-09-27 |
Comment on"Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment": Is real-world evidence real?
|
Chen, C;Hsiao, CF |
| 國家衛生研究院 |
2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, L;Chen, MH |
| 國家衛生研究院 |
2021-05 |
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial
|
Pen, SL;Shan, YS;Hsiao, CF;Liu, TW;Chen, JS;Ho, CL;Chou, WC;Hsieh, RK;Chen, LT;Ch'ang, HJ |
| 國家衛生研究院 |
2021-05 |
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy
|
Bai, LY;Yang, MH;Chiang, NJ;Wu, SY;Lin, CY;Lien, MY;Chen, JH;Chang, MH;Hsieh, CY;Hong, RL;Kao, HF;Ye, RH;Chen, SH;Hsiao, CF;Chen, LT;Liu, TW |
| 國家衛生研究院 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Bai, LY;Li, CP;Chen, JS;Yang, SH;Kuo, YC;Chao, Y;Hsieh, YY;Kao, HF;Hsiao, CF;Chen, LT |
| 國家衛生研究院 |
2021-02-05 |
Tolerance interval testing for assessing accuracy and precision simultaneously
|
Chiang, C;Hsiao, CF |
| 中山醫學大學 |
2021 |
Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia
|
Blechter, B; Wong, JYY; Hsiung, CA; Hosgood, HD; Yin, ZH; Shu, XO; Zhang, H; Shi, JX; Song, L; Song, MS; Zheng, W; Wang, ZM; Caporaso, N; Burdette, L; Yeager, M; Berndt, SI; Landi, MT; Chen, CJ; Chang, GC; Hsiao, CF; Tsai, YH; Chen, KY; Huang, MS; Su, WC; Chen, YM; Chien, LH; Chen, CH; Yang, TY; Wang, CL; Hung, JY; Lin, CC; Perng, RP; Chen, CY; Chen, KC; Li, YJ; Yu, CJ; Chen, YS; Chen, YH; Tsai, FY; Seow, WJ; Bassig, BA; Hu, W; Ji, BT; Wu, W; Guan, P; He, QC; Gao, YT; Cai, QY; Chow, WH; Xiang, YB; Lin, DX; Wu, C; Wu, YL; Shin, MH; Hong, YC; Matsuo, K; Chen, KX; Wong, MP; Lu, DR; Jin, L; Wang, JC; Seow, A; Wu, TC; Shen, HB; Fraumeni, JF; Yang, PC; Chang, IS; Zhou, BS; Chanock, SJ; Rothman, N; Chatterjee, N; Lan, Q |
| 國家衛生研究院 |
2020-12-29 |
Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia
|
Blechter, B;Wong, JYY;Agnes Hsiung, C;Hosgood, HD;Yin, Z;Shu, XO;Zhang, H;Shi, J;Song, L;Song, M;Zheng, W;Wang, Z;Caporaso, N;Burdette, L;Yeager, M;Berndt, SI;Teresa Landi, M;Chen, CJ;Chang, GC;Hsiao, CF;Tsai, YH;Chen, KY;Huang, MS;Su, WC;Chen, YM;Chien, LH;Chen, CH;Yang, TY;Wang, CL;Hung, JY;Lin, CC;Perng, RP;Chen, CY;Chen, KC;Li, YJ;Yu, CJ;Chen, YS;Chen, YH;Tsai, FY;Jie Seow, W;Bassig, BA;Hu, W;Ji, BT;Wu, W;Guan, P;He, Q;Gao, YT;Cai, Q;Chow, WH;Xiang, YB;Lin, D;Wu, C;Wu, YL;Shin, MH;Hong, YC;Matsuo, K;Chen, K;Pik Wong, M;Lu, D;Jin, L;Wang, JC;Seow, A;Wu, T;Shen, H;Fraumeni, JF;Yang, PC;Chang, IS;Zhou, B;Chanock, SJ;Rothman, N;Chatterjee, N;Lan, Q |
| 國家衛生研究院 |
2020-12-09 |
On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes
|
Hamasaki, T;Hung, HMJ;Hsiao, CF;Evans, SR |
| 國家衛生研究院 |
2020-12-02 |
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
|
Chen, CP;Lin, YC;Chen, TC;Tseng, TY;Wong, HL;Kuo, CY;Lin, WP;Huang, SR;Wang, WY;Liao, JH;Liao, CS;Hung, YP;Lin, TH;Chang, TY;Hsiao, CF;Huang, YW;Chung, WS;Cheng, CY;Cheng, SH |
| 國家衛生研究院 |
2020-09-01 |
Use of a two-sided tolerance interval in the design and evaluation of biosimilarity in clinical studies
|
Chiang, C;Chen, CT;Hsiao, CF |
顯示項目 6-30 / 204 (共9頁)
1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
